Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-cash Items (2016 - 2024)

Historic Non-cash Items for Heron Therapeutics (HRTX) over the last 10 years, with Q4 2024 value amounting to $9.6 million.

  • Heron Therapeutics' Non-cash Items rose 689927.01% to $9.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $9.6 million, marking a year-over-year increase of 689927.01%. This contributed to the annual value of $9.6 million for FY2024, which is 689927.01% up from last year.
  • According to the latest figures from Q4 2024, Heron Therapeutics' Non-cash Items is $9.6 million, which was up 689927.01% from $137000.0 recorded in Q4 2023.
  • Over the past 5 years, Heron Therapeutics' Non-cash Items peaked at $69.1 million during Q4 2020, and registered a low of $137000.0 during Q4 2023.
  • In the last 4 years, Heron Therapeutics' Non-cash Items had a median value of $5.6 million in 2021 and averaged $20.1 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first tumbled by 9753.98% in 2021, then soared by 689927.01% in 2024.
  • Quarter analysis of 4 years shows Heron Therapeutics' Non-cash Items stood at $69.1 million in 2020, then plummeted by 97.54% to $1.7 million in 2021, then tumbled by 91.94% to $137000.0 in 2023, then skyrocketed by 6899.27% to $9.6 million in 2024.
  • Its last three reported values are $9.6 million in Q4 2024, $137000.0 for Q4 2023, and $1.7 million during Q4 2021.